Seer, Inc. (NASDAQ:SEER) Short Interest Update

Seer, Inc. (NASDAQ:SEER) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 978,800 shares, a growth of 31.0% from the October 15th total of 747,300 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average trading volume of 290,000 shares, the short-interest ratio is presently 3.4 days.

Institutional Investors Weigh In On Seer

A number of hedge funds have recently made changes to their positions in SEER. AQR Capital Management LLC bought a new stake in Seer during the 2nd quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Seer during the first quarter valued at approximately $35,000. Point72 DIFC Ltd acquired a new stake in shares of Seer in the second quarter valued at approximately $35,000. Quadrature Capital Ltd bought a new position in Seer in the 1st quarter worth approximately $56,000. Finally, American Century Companies Inc. lifted its holdings in Seer by 42.1% during the 2nd quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock worth $104,000 after buying an additional 18,302 shares in the last quarter. Institutional investors and hedge funds own 75.20% of the company’s stock.

Seer Stock Down 4.5 %

Seer stock traded down $0.11 during mid-day trading on Friday, hitting $2.31. 492,426 shares of the company were exchanged, compared to its average volume of 446,587. Seer has a 1-year low of $1.46 and a 1-year high of $2.50. The business has a fifty day moving average of $1.93 and a 200 day moving average of $1.86. The company has a market capitalization of $141.90 million, a PE ratio of -1.78 and a beta of 1.45.

Analysts Set New Price Targets

Separately, Morgan Stanley lowered their price objective on Seer from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 13th.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.